Skip to main content
SpringerLink
Log in

Once-Daily Inhaled Corticosteroids in Children with Asthma

Dry Powder Inhalers

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The cornerstone of pharmacological management of asthma in childhood is inhaled corticosteroids. These drugs are intended for long term treatment and, consequently, compliance is a major issue. Once-daily administration of maintenance medication would simplify treatment and it is likely that it would lead to better compliance. Moreover, the excellent safety profile of inhaled corticosteroid treatment tailored to disease severity may, theoretically, be further improved with once-daily administration.

Studies comparing inhaled corticosteroids given once or twice daily to patients with asthma indicate that unstable asthma is best treated with at least 2 daily doses. On the other hand, it has been demonstrated that, if the asthma is stabilised, most children can be treated with inhaled corticosteroids once daily without loss of efficacy.

Thus, the data suggest that newly diagnosed asthma, or asthma after deterioration, should first be reliably controlled with inhaled corticosteroids divided into at least 2 daily doses. Once-daily maintenance treatment should then be tried with the aim of improving compliance and quality of life. A dry powder inhalation device is probably the best choice for children from the age of 5 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy 1992; 47 Suppl. 13: 1–61

    Google Scholar 

  2. Anon. Asthma: a follow up statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67: 240-8

  3. Global Initiative for Asthma. NHLBI/WHO Workshop report. NIH Publication 95-3659. Bethesda: National Heart, Lung and Blood Institute, National Institutes of Health, 1995

    Google Scholar 

  4. Dahl R, Bjermer L, editors. Nordic consensus report on asthma management. Respir Med 1999; 93

  5. Bousquet J, Lockey RF, Mailing H-J, editors. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 Suppl. 44: 1–42

    Google Scholar 

  6. Nakamura Y, Hoshino M, Sim JJ, et al. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835–41

    Article  PubMed  CAS  Google Scholar 

  7. Palmqvist M, Balder B, Lowhagen O, et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. J Allergy Clin Immunol 1992; 89: 844–9

    Article  PubMed  CAS  Google Scholar 

  8. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102: 531–8

    Article  PubMed  CAS  Google Scholar 

  9. Simons FE. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 1998; 102: S77–84

    Article  PubMed  CAS  Google Scholar 

  10. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–81

    Article  PubMed  CAS  Google Scholar 

  11. van Essen-Zandvliet EE, Dutch Chronic Nonspecific Lung Disease Study Group. Long-term intervention in childhood asthma: the Dutch study results. Mon Arch Chest Dis 1995; 50: 201–7

    Google Scholar 

  12. Hussar DA. Patient non-compliance. J Am Pharm Assoc 1975; 15: 183–201

    PubMed  CAS  Google Scholar 

  13. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7

    Article  PubMed  CAS  Google Scholar 

  14. Mann M, Eliasson O, Patel K, et al. A comparison of effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101: 496–9

    Article  PubMed  CAS  Google Scholar 

  15. Matthew D, Hingson R. Improving patient compliance: aguide for physicians. Med Clin North Am 1971; 61: 879–89

    Google Scholar 

  16. McAllister WA, Hetzel M, Emery P, et al. Comparison of efficacy and adrenal suppression produced by alternate-day, daily and twice-daily prednisolone regimens for chronic asthma. Thorax 1983; 38: 230–1

    Google Scholar 

  17. Toogood J, Jennings B, Lefcoe N. Morning-dose beclomethasone aerosol (BA) is clinically effective and spares adrenal function. Ann R Coll Phys Surg (Can) 1980; 13: 110

    Google Scholar 

  18. Toogood JH, Baskerville JC, Jennings B,et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol 1982; 70: 288–98

    Article  PubMed  CAS  Google Scholar 

  19. Byron MA, Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983; 76: 452–7

    PubMed  CAS  Google Scholar 

  20. Casaneuva FF, Burguera B, Tome MA. Depending on the time of administration, dexamethasone potentiates or blocks growth hormone release in man. Neuroendocrinology 1990; 51: 46–91

    Google Scholar 

  21. Heuck C, Wolthers OD, Kollerup G, et al. Adverse effects of inhaled budesonide (800μg) on growth and collagen tunover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133: 608–12

    Article  PubMed  CAS  Google Scholar 

  22. Dahl R, Johansson SA. Clinical effect of b.i.d. and q.i.d. administration of inhaled budesonide, a double-blind controlled study. Eur J Respir Dis 1982; 63 Suppl. 122: 268–9

    Google Scholar 

  23. Toogood JH. Concentrated aerosol formulations in asthma. Lancet 1983; 2: 790–1

    Article  PubMed  CAS  Google Scholar 

  24. Malo JL, Ghezzo H, Trudeau C, et al. Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperven-tilation of dry cold air in asthmatic subjects. Am Rev Respir Dis 1989; 140: 817–21

    PubMed  CAS  Google Scholar 

  25. Malo J-L, Cartier A, Ghezzo H, et al. Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med 1995; 89: 537–43

    Article  PubMed  CAS  Google Scholar 

  26. Mecoy R, Laby B. Beclomethasone dipropionate in twice daily treatment of asthma. Aust Fam Physician 1980; 9: 721–8

    PubMed  CAS  Google Scholar 

  27. Munch EP, Taudorf E, Weeke B. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Eur J Respir Dis 1982; 63: 143

    Google Scholar 

  28. Nyholm E, Frame MH, Cayton RM. Therapeutic advantage of twice-daily over four-times-daily inhalation budesonide in the treatment of chronic asthma. Eur J Respir Dis 1984; 65: 339–45

    PubMed  CAS  Google Scholar 

  29. Meltzer EO, Kemp JP, Welch MJ, et al. Effect of dosing schedule on efficacy of beclomethasone dipropionate aerosol in chronic asthma. Am Rev Respir Dis 1985; 131: 732–6

    PubMed  CAS  Google Scholar 

  30. Boyd G, Abdallah S, Clark R. Twice or four times daily beclomethasone dipropionate in mild stable asthma? Clin Allergy 1985; 15: 383–9

    Article  PubMed  CAS  Google Scholar 

  31. So SY, Lam WK. Twice daily administration of beclomethasone dipropionate dry-powder in the management of chronic asthma. Asian Pac J Allergy Immunol 1986; 4: 129–32

    PubMed  CAS  Google Scholar 

  32. Williams H, Jones ER, Silbert JR. Twice daily versus four times daily treatment with beclomethasone dipropionate in the control of mild childhood asthma. Thorax 1986; 41: 602–5

    Article  PubMed  CAS  Google Scholar 

  33. Smith MJ, Hodson ME. Twice daily beclomethasone dipropionate administered with a concentrated aerosol inhaler: efficacy and patient compliance. Thorax 1986; 41: 960–3

    Article  PubMed  CAS  Google Scholar 

  34. Tukiainen H, Vaara J, Terho E, et al. Comparison of twice-daily and four-times daily administration of beclomethasone dipropionate in patients with severe chronic bronchial asthma. Eur J Clin Pharmacol 1986; 30: 319–22

    Article  PubMed  CAS  Google Scholar 

  35. Reinberg A, Halberg F, Falliers CJ. Circadian timing of methylprednisolone effects in asthmatic boys. Chronobiologia 1974; 1: 333–47

    PubMed  CAS  Google Scholar 

  36. Pincus DJ, Szefler SJ, Ackerson LM, et al. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995; 95: 1172–8

    Article  PubMed  CAS  Google Scholar 

  37. Gagnon M, Cote J, Milot J, et al. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest 1994; 105: 1732–7

    Article  PubMed  CAS  Google Scholar 

  38. McGivern DV, Ward M, Macfarlane JT, et al. Failure of once daily inhaled corticosteroid treatment to control chronic asthma. Thorax 1984; 39: 933–4

    Article  PubMed  CAS  Google Scholar 

  39. Stiksa G, Glennow C. Once daily inhalation of budesonide in the treatment of chronic asthma: a clinical comparison. Ann Allergy 1985; 55: 49–51

    PubMed  CAS  Google Scholar 

  40. Munch EP, Laursen LC, Dirksen A, et al. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Comparison between a twice daily and a once daily dosing regimen. Eur J Respir Dis 1985; 67: 254–60

    CAS  Google Scholar 

  41. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293–9

    Article  PubMed  CAS  Google Scholar 

  42. Campbell LM, Gunn SD, Sweeney D, et al. Once daily budesonide: effective control of moderately severe asthma with 800 lig once daily inhaled via Turbuhaler when compared with 400 μg twice daily. Eur J Clin Res 1995; 7: 1–14

    Google Scholar 

  43. Weiner P, Weiner M, Azgad Y. Long-term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 1995; 50/12: 1270–3

    Article  Google Scholar 

  44. ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol 1997; 99: 278–85

    Article  PubMed  CAS  Google Scholar 

  45. Chisholm SL, Dekker FW, Knuistingh Neven A, et al. Once-daily budesonide in mild asthma. RespirMed 1998; 92: 421–5

    CAS  Google Scholar 

  46. Venables TL, Addlestone MB, Smithers AJ, et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbuhaler and twice daily fluticasone propionate via Diskhaler at an equal daily dose of 400 mcg in adult asthmatics. Br J Clin Res 1996; 7: 15–32

    Google Scholar 

  47. Johansson L-O. A comparison of once-daily fluticasone propionate (FP) 200 μg and budesonide (bud) 400 μg and twice-daily of fluticasone propionate (FP) 100 μg [abstract]. Am J Resp Crit Care Med 1998; 157 (3 Pt 2): A404

    Google Scholar 

  48. Miller-Lars son A, Mattson H, Ohlsson D, et al. Prolonged release from the airways tissue of glucocorticoids BUD and fluticasone dipropionate as compared to beclomethasone dipropionate and hydrocortisone. Am J Respir Crit Care Med 1994; 149 (4 Pt 2): A466

    Google Scholar 

  49. Brattsand R, Miller-Larsson A, Wieslander E, et al. Reversible fatty acid conjugation of budesonide — a mechanism contributing to prolonged local retention and activity. Eur Respir J 1997; 10 Suppl. 25: 296S

    Google Scholar 

  50. Miller-Larsson A, Jansson P, Runström A, et al. Reversible fatty acid conjugation of budesonide results in a prolonged topical anti-inflammatory activity in airways as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353

    Google Scholar 

  51. Miller-Larsson A, Hjertberg E, Mattson H, et al. Reversible fatty acid conjugation of budesonide results in a prolonged retention in airway tissue as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353

    Google Scholar 

  52. Wieslander E, Delander EL, Järkelid L, et al. Reversible fatty acid conjugation of budesonide results in prolonged anti-inflammatory activity as compared to fluticasone propionate. Am J Respir Crit Care Med 1997; 155 (4 Pt 2): A353

    Google Scholar 

  53. Agertoft L, Pedersen S. Importance of training for correct Turbuhaler use in preschool children. ActaPaediatr 1998; 87: 842–7

    CAS  Google Scholar 

  54. de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996; 98: 14–20

    Article  PubMed  Google Scholar 

  55. Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993; 68: 356–9

    Article  PubMed  CAS  Google Scholar 

  56. Bingham A, Manjra AL, Lee BW, et al. A comparison of the effect of nebulised fluticasone propionate 1mg twice daily with oral prednisolone in children aged 4–16 years with an acute exacerbation of asthma. Am J Respir Crit Care Med 1998; 157(3): A404

    Google Scholar 

  57. Francis P, Geelhoed G, Harris MA, et al. Effect of nebulised fluticasone propionate lmg twice daily compared with oral prednisolone in pre-school children aged 48 months or less with an acute exacerbation of asthma. Eur Respir J 1997; 10 Suppl. 25: 275S

    Google Scholar 

  58. Webb MS, Milner AD, Hiller EJ, et al. Nebulised beclomethasone dipropionate suspension. Arch Dis Child 1986; 61(11): 1108–10

    Article  PubMed  CAS  Google Scholar 

  59. Agertoft L, Andersen A, Weibull E, et al. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999; 80(3): 241–7

    Article  PubMed  CAS  Google Scholar 

  60. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308–19

    Article  PubMed  CAS  Google Scholar 

  61. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler (P-MDI). Eur Respir J 1994;7: 1839–44

    Article  PubMed  CAS  Google Scholar 

  62. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69(1): 130–3

    Article  PubMed  CAS  Google Scholar 

  63. Pauwels RA, Hargreave FE, Camus P, et al. A 1-year comparison of Turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Chest 1996; 110: 53–7

    Article  PubMed  CAS  Google Scholar 

  64. Schlaeppi M, Edwards K, Fuller RW, et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract 1996; 50(1): 14–9

    PubMed  CAS  Google Scholar 

  65. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11(5): 1111–5

    Article  PubMed  CAS  Google Scholar 

  66. Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulmon Pharmacol Ther 1997; 10(4): 211–4

    Article  CAS  Google Scholar 

  67. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from Turbuhaler in asthmatic children. Eur JPediatr 1998; 157(12): 1017–22

    Article  CAS  Google Scholar 

  68. Bisgaard H, Pedersen S, Nikander K. Use of budesonide Turbuhaler in young children suspected of asthma. Eur Respir J 1994; 7: 740–2

    Article  PubMed  CAS  Google Scholar 

  69. McCarthy TP. The use of a once daily inhaled glucocorticosteroid (budesonide) in the management of childhood asthma. Br J Clin Res 1993; 4: 55–61

    Google Scholar 

  70. Campbell LM, Bodalia B, Gogbashian CA, PETITE Research Group, et al. Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. Int J Clin Practice 1998; 52: 213–9

    CAS  Google Scholar 

  71. Jónasson G, Carlsen KH, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12: 1099–104

    Article  PubMed  Google Scholar 

  72. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–54

    PubMed  Google Scholar 

  73. Möller C, Strömberg L, Oldaeus G, et al. Efficacy of once-daily versus twice-daily administration of budesonide via Turbuhaler in children with stable asthma. Pediatr Pulmonol. In press

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Umeå University, S-901 85, Umeå, Sweden

    Christian Möller

Authors
  1. Christian Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Möller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möller, C. Once-Daily Inhaled Corticosteroids in Children with Asthma. Drugs 58 (Suppl 4), 35–41 (1999). https://doi.org/10.2165/00003495-199958004-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958004-00005

Keywords

Search

Navigation